Advertisement

Tumor Biology

, Volume 35, Issue 11, pp 11381–11389 | Cite as

TES was epigenetically silenced and suppressed the epithelial–mesenchymal transition in breast cancer

  • Yang Yongbin
  • Li Jinghua
  • Zhao Zhanxue
  • Zang Aimin
  • Jia Youchao
  • Shang YanhongEmail author
  • Jiao Manjing
Research Article

Abstract

The TES gene was frequently lost in breast cancer, which could inhibit tumor invasion and the formation of distant metastasis. However, the underlying mechanisms remain unknown yet. In the present study, we aimed to investigate how TES was silenced and its roles in EMT—the key step for tumor metastasis. Real-time polymerase chain reaction (PCR) and Western blot were used to detect the mRNA and protein expression of target genes; the status of TES promoter was determined by methylation-specific PCR and subsequently, DNA sequencing. Overexpression or downregulation of TES was achieved by pcDNA3.1-TES or shRNA-TES transfection. Cellular adhesion and migration were investigated by the adhesion and Transwell assays. Morphological changes of breast cancer cells were observed under the optical microscope. The Rho A activity was measured using a commercial kit, and its roles in TES-manipulated EMT were determined by real-time PCR and Western blot. The 42.3 % (33/78) breast cancer tissues presented hypermethylation of the TES gene, whereas only 2 (2.6 %) non-malignant cases were hypermethylated (P < 0.001). Moreover, TES hypermethylation was significantly correlated with larger tumor diameter (P = 0.03) and lympho node metastasis (P = 0.024). In primary cultured breast cancer cells, the demethylation treatment using 5-aza-dC notably restored the expression of TES. In vitro, overexpression of TES enhanced cellular adhesion inhibited migration and suppressed EMT, while downregulation of TES impaired cellular adhesion, promoted migration, and enhanced EMT. TES overexpression also activated the Rho A signal, which is a critical factor for the effects of TES on the EMT procedure. We firstly proved that frequent loss of TES in breast cancer was caused by promoter hypermethylation, which was correlated with poor prognosis. In vitro, TES enhanced cellular adhesion, suppressed tumor migration, and inhibited EMT. Moreover, the Rho A pathway was critical for the effects of TES on EMT, which can be blocked by the Rho A inhibitor. Therefore, we propose restoration of TES as a potent strategy for breast cancer therapy.

Keywords

Breast cancer The TES gene Tumor suppressor Hypermethylation EMT 

Notes

Acknowledgments

This work was supported by the grants from the Hebei University, Administration of Traditional Chinese Medicine of Hebei Province, Research Center for Eco-Environmental Sciences of the Chinese Academy of Sciences (Nos. 2012A1002,2011213, KF2010-17, and 2008071).

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Poortmans P, Marsiglia H, De Las Heras M, Algara M. Clinical and technological transition in breast cancer. Rep Pract Oncol Radiother. 2013;18(6):345–52.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Banin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular markers for breast cancer: prediction on tumor behavior. Dis Markers. 2014;2014:513158.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Rivenbark AG, O’Connor SM, Coleman WB. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. Am J Pathol. 2013;183(4):1113–24.PubMedCrossRefGoogle Scholar
  7. 7.
    Huang H, Qian C, Jenkins RB, Smith DI. Fish mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Gene Chromosome Cancer. 1998;21(2):152–9.CrossRefGoogle Scholar
  8. 8.
    Huang H, Qian J, Proffit J, Wilber K, Jenkins R, Smith DI. FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites. Oncogene. 1998;16(18):2311–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Tatarelli C, Linnenbach A, Mimori K, Croce CM. Characterization of the human TESTIN gene localized in the FRA7G region at 7q31.2. Genomics. 2000;68(1):1–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhu J, Li X, Kong X, Moran MS, Su P, Haffty BG, et al. Testin is a tumor suppressor and prognostic marker in breast cancer. Cancer Sci. 2012;103(12):2092–101.PubMedCrossRefGoogle Scholar
  11. 11.
    Drusco A, Zanesi N, Roldo C, Trapasso F, Farber JL, Fong LY, et al. Knockout mice reveal a tumor suppressor function for testin. Proc Natl Acad Sci U S A. 2005;102(31):10947–51.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Tobias ES, Hurlstone AF, MacKenzie E, McFarlane R, The BDM, TES. Gene at 7q31.1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein. Oncogene. 2001;20(22):2844–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Chene L, Giroud C, Desgrandchamps F, Boccon-Gibod L, Cussenot O, Berthon P, et al. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer. 2004;111(5):798–804.PubMedCrossRefGoogle Scholar
  14. 14.
    Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, et al. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene. 2007;26(4):583–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Sarti M, Sevignani C, Calin GA, Aqeilan R, Shimizu M, Pentimalli F, et al. Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. Clin Cancer Res. 2005;11(2 Pt 1):806–13.PubMedGoogle Scholar
  16. 16.
    Coutts AS, MacKenzie E, Griffith E, Black DM. TES is a novel focal adhesion protein with a role in cell spreading. J Cell Sci. 2003;116(Pt 5):897–906.PubMedCrossRefGoogle Scholar
  17. 17.
    Garvalov BK, Higgins TE, Sutherland JD, Zettl M, Scaplehorn N, Kocher T, et al. The conformational state of Tes regulates its zyxin-dependent recruitment to focal adhesions. J Cell Biol. 2003;161(1):33–9.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Griffith E, Coutts AS, Black DM. Characterisation of chicken TES and its role in cell spreading and motility. Cell Motil Cytoskeleton. 2004;57(3):133–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.PubMedCrossRefGoogle Scholar
  20. 20.
    Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003;4(8):657–65.PubMedCrossRefGoogle Scholar
  21. 21.
    Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33.PubMedCrossRefGoogle Scholar
  22. 22.
    Bastid J. EMT in carcinoma progression and dissemination: facts, unanswered questions, and clinical considerations. Cancer Metastasis Rev. 2012;31(1–2):277–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Minafra L, Norata R, Bravata V, Viola M, Lupo C, Gelfi C, et al. Unmasking epithelial–mesenchymal transition in a breast cancer primary culture: a study report. BMC Res Notes. 2012;5:343.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Qiu H, Zhu J, Yuan C, Yan S, Yang Q, Kong B. Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer. Cancer Sci. 2010;101(5):1255–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Jones PA. DNA methylation and cancer. Oncogene. 2002;21(35):5358–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Gunduz E, Gunduz M, Beder L, Nagatsuka H, Fukushima K, Sutcu R, et al. Downregulation of TESTIN and its association with cancer history and a tendency toward poor survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2009;135(3):254–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform. 2013;11(4):164–73.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy. Epigenomics. 2013;5(1):87–94.PubMedCrossRefGoogle Scholar
  29. 29.
    Hagrass HA, Pasha HF, Shaheen MA, Abdel Bary EH, Kassem R. Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep. 2014;41(1):57–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Kang HF, Dai ZJ, Bai HP, Lu WF, Ma XB, Bao X, et al. RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line. Onco Targets Ther. 2013;6:411–7.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Askari M, Sobti RC, Nikbakht M, Sharma SC. Aberrant promoter hypermethylation of p21 (WAF1/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer. Mol Cell Biochem. 2013;382(1–2):19–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Pulling LC, Grimes MJ, Damiani LA, Juri DE, Do K, Tellez CS, et al. Dual promoter regulation of death-associated protein kinase gene leads to differentially silenced transcripts by methylation in cancer. Carcinogenesis. 2009;30(12):2023–30.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Griffith E, Coutts AS, Black DM. RNAi knockdown of the focal adhesion protein TES reveals its role in actin stress fibre organisation. Cell Motil Cytoskeleton. 2005;60(3):140–52.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yang Yongbin
    • 1
  • Li Jinghua
    • 2
  • Zhao Zhanxue
    • 1
  • Zang Aimin
    • 2
  • Jia Youchao
    • 2
  • Shang Yanhong
    • 2
    Email author
  • Jiao Manjing
    • 3
  1. 1.Health Science CenterHebei UniversityBaodingPeople’s Republic of China
  2. 2.Department of OncologyAffiliated Hospital of Hebei UniversityBaodingPeople’s Republic of China
  3. 3.Clinical LabZhuozhou City HospitalZhuozhouPeople’s Republic of China

Personalised recommendations